ROS/KRAS/AMPK signaling determines gemcitabine-induced pancreatic cancer stem-like cell property  in vitro

Hengqiang Zhao; Hehe Li; Qingke Duan; Zhengle Zhang; Heshui Wu; Qiang Shen; Chunyou Wang; Tao Yin

doi:10.18632/oncotarget.24081

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Withdrawal Notice

This paper was originally published in Oncotarget Advance Online Publications on 01/09/2018.
In compliance with Oncotarget's withdrawal policy, the paper was withdrawn in its entirety. It will not appear in Oncotarget internal or any external indexes or archives.

Research Papers:

ROS/KRAS/AMPK signaling determines gemcitabine-induced pancreatic cancer stem-like cell property in vitro

Hengqiang Zhao, Hehe Li, Qingke Duan, Zhengle Zhang, Heshui Wu, Qiang Shen, Chunyou Wang and Tao Yin _

Hengqiang Zhao1, Hehe Li1, Qingke Duan1, Zhengle Zhang1, Heshui Wu1, Qiang Shen2, Chunyou Wang1 and Tao Yin1

1Department of Pancreatic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

2Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Correspondence to:

Tao Yin, email: [email protected]

Chunyou Wang, email: [email protected]

Keywords: ROS; KRAS; AMPK; glycolysis; cancer stem cells

Received: June 20, 2017 Accepted: January 04, 2018 Published: January 09, 2018

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24081

Publication Alerts

Post-Publication Promotion

Publication Discount

Withdrawal Notice

Research Papers:

ROS/KRAS/AMPK signaling determines gemcitabine-induced pancreatic cancer stem-like cell property in vitro